TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02682927
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution for ZX008. The product is sugar free and is intended to be compatible with a ketogenic diet.
Study: NCT01621477
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given on Day -5 and Day +4 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent; immunosuppressive agent.
Study: NCT02851745
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00217737
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00217737
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01948531
Drug: Gynomunal® gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: A fixed quantity of the cosmetic product will be applied on the face (including the submental area) twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage according to the instructions received by the investigator during the basal visit (T0).
Study: NCT02669862
Drug: A-101 Solution 40
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02669862
Drug: A-101 Solution 45
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02669862
Drug: Vehicle Solution
Normalized name: compounding vehicle solution sugar free no. 1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02397694
Drug: BIC Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily
Study: NCT02397694
Drug: DTG Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily
Study: NCT02397694
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50/200/25 mg FDC tablet administered orally once daily
Study: NCT01694420
Drug: (FDC) ELV/COBI/FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral treatment
Study: NCT01566643
Drug: RA5-RACM7
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 20mg bid + amoxicillin 1g bid treated for 5 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
Study: NCT02226601
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 days perioperative Placebot once a day
Study: NCT03483363
Drug: topical irrigation with gentamicin (80mg diluted in 1L 0.9% normal saline)
Normalized name: gentamicin Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractures will be irrigated with the topical antibiotic gentamicin (80mg diluted in 1L 0.9% normal saline) prior to closure.
Study: NCT00394563
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01952314
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aceclofenac 100mg or tramadol37.5mg/acetaminophen 325mg on demand
Study: NCT03283384
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose dense AC-T chemotherapy: consisting of 4 cycles of AC (doxorubicin and cyclophosphamide at a dose of 60 and 600 mg/m² as an i.v. bolus, respectively) 2-weekly, plus G-CSF (6 mg once per cycle) 24-48 hr after chemotherapy, followed by cycles of T (4 cycles docetaxel 100 mg/m² 3-weekly or 12 cycles paclitaxel 80 mg/m2 weekly).
Study: NCT01566643
Drug: RA3-RACM7
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 20mg bid + amoxicillin 1g bid treated for 3 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
Study: NCT01566643
Drug: RA7-RACM7
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 20mg bid + amoxicillin 1g bid treated for 7 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
Study: NCT04669041
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study: NCT04669041
Drug: SPC ezetimibe/rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study: NCT04669041
Drug: Rosuvastatin active capsule
Normalized name: rosuvastatin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Capsule Route of administration: Oral
Study: NCT04669041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study: NCT04669041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Capsule Route of administration: Oral
Study: NCT04446923
Drug: Hand antisepsis by scrub
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical Hand scrubbing using P-1 of both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side.
Study: NCT00758966
Drug: Fluoxetine 60 mg
Normalized name: fluoxetine 60 MG
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two week titration followed by daily dosing of fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on fluoxetine 60 mg for an additional 6 weeks. Non-responders will have naltrexone SR 32 mg added to their therapy.
Study: NCT00758966
Drug: Naltrexone 32 mg and fluoxetine 60 mg
Normalized name: fluoxetine hydrochloride 32 MG
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two week titration followed by daily dosing of naltrexone SR 32 mg and fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on a daily dose of naltrexone SR 32 mg and fluoxetine 60 mg for an additional 6 weeks. Non-responders will have their daily dose adjusted to naltrexone SR 48 mg and fluoxetine 80 mg.
Study: NCT00736437
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment applied 6 times daily over the UVR exposed area
Study: NCT03656588
Drug: a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol
Study: NCT00015873
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00015873
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00015873
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03449446
Drug: FIR
Normalized name: Firox
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tablet administered orally once daily without regard to food
Study: NCT03449446
Drug: Placebo to match FIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily without regard to food
Study: NCT03449446
Drug: Placebo to match CILO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily without regard to food
Study: NCT03449446
Drug: Placebo to match SEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily without regard to food
Study: NCT03883802
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months treatment regimen
Study: NCT01206010
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will increase placebo dose by 0.5 mg twice daily every three days to a maximum of 2.5 mg twice daily. This increased dose will be continued for 3-weeks before being reduced to the standard varenicline dose of 1.0 mg twice daily.
Study: NCT00289120
Drug: Cola beverage
Normalized name: cola extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be given 500cc of Cola beverage twice daily to be ingested with breakfast and dinner for six days while on a metabolic diet.There will be a three weeks interval before crossover to the other treatment arm.
Study: NCT00286026
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children \> 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg. One dose vs 2 doses given 30 days apart.
Study: NCT00553735
Drug: Arificial Tear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial Tear - three times a day for 18 months.
Study: NCT00451646
Drug: SMOF lipid and Intralipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-2 g, 5-7 days, 28 days
Study: NCT03765788
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone was provided as tablets (1 mg, 5 mg, 10 mg, 20 mg tablets) for daily administration as tapered regimen from a dose of 25 mg to 60 mg at Baseline to 1 mg at Week 26 (last dose)
Study: NCT03765788
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 300 mg was administered by subcutaneous (s.c.) injections using 1 mL pre-filled syringes (PFSs) throughout the study.
Study: NCT01057069
Drug: Doxorubicin, cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-weekly administrations of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.
Study: NCT01057069
Drug: Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: One course of of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin. PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.~This course is followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
Study: NCT00651404
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet; ezetimibe placebo daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)
Study: NCT02648958
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group received the normal saline infusion
Study: NCT03009201
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01151046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (histidine solution) administered over 60 minutes as an intravenous infusion once per week and exemestane (25 mg) administered orally once per day
Study: NCT00610610
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same shape Placebo
Study: NCT01940991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, Dose B; dose applied to the lateral canthal lines
Study: NCT01917916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for subcutaneous (s.c.) injection.
Study: NCT00216138
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 825 mg/m2 po bid, days 1-14
Study: NCT04007198
Drug: EQ001 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: EQ001 Placebo
Study: NCT04471064
Drug: XY0206
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form:Tablet;Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the withdrawal criteria. The duration and interval of treatment were determined according to the accumulated condition after multiple dose.
Study: NCT02147964
Drug: Testosterone 1% Gel
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone 1% gel 5g daily for 4 months \[all subjects\]
Study: NCT01863407
Drug: DAM
Normalized name: dAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: composed of dexamethasone, allantoin and metronidazole
Study: NCT01863407
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline 250ml
Study: NCT02500043
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg/m2/dose of placebo orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
Study: NCT01371747
Drug: spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone dose: 25 mg/d or up to 50 mg/d, oral, once daily (initiated during Run-In Period; Cohort 2)
Study: NCT00411411
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01415102
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled
Study: NCT03395457
Drug: Care as usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of usual pharmacological care for chronic migraine
Study: NCT04348695
Drug: Ruxolitinib plus simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 5 mg orally every 12 hours for 7 days, which will be increased to 10 mg every 12 hours for a total of 14 days.~Simvastatin 40 mg orally every 24 hours for 14 days
Study: NCT00002780
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00948662
Drug: Placebo of SAM-760
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAM-760 matching placebo capsule, single dose, 1 day,
Study: NCT03428412
Drug: TCM placebo and conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.~The control group will receive TCM placebo according to the TCM syndrome. Placebo Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days.~Placebo Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days.~Placebo Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days.
Study: NCT00319228
Drug: Plasma-derived AT-III concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Segment I: A single dose IV infusion of 50 IU/kg of ATIII-DAF/DI will be administered to each patient.~Segment II: A single dose or multiple doses depending on the subject's ATIII plasma levels and patient's specific treatment plan.
Study: NCT00696787
Drug: Lyrica® (Pregabalin)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00696787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01261923
Drug: Alitretinoin
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg capsule of 9-cis-retinoic-acid (9-cis-RA)(Alitretinoin, Toctino®)
Study: NCT01146756
Drug: AZD6244
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEK inhibitor AZD6244 (Selumentinib) in combination with thoracic radiotherapy
Study: NCT00005050
Drug: ethynyluracil
Normalized name: 5-Ethynyluracil
DrugBank: Eniluracil (DB03516)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005050
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00702156
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
Study: NCT00039442
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT01911845
Drug: ABT-450/r/ABT-267
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267
Study: NCT01911845
Drug: ABT-333
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT00131495
Drug: Testosterone (transdermal patches)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone patch (300mcg/day, changed twice a week for one year
Study: NCT02765763
Drug: 24/7 Barrier Repair Cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02765763
Drug: 8-in-1 BioSerum
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02765763
Drug: Null Formula 24/7 Barrier Repair Cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02765763
Drug: Null Formula 8-in-1 BioSerum
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03059797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
Study: NCT02213653
Drug: ARM B: IV iron + epoietin zeta sequence
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Epoietin zeta at a dose of 450 IU / kg per week subcutaneously started in week 7~* carboxymaltose ferric (Ferinject ®) at week 1~  * Intravenous infusion not exceeding 1000 mg (administered once if weight\> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).~ * Renewable with a minimum of 4 weeks depending on the iron status (if CST \<20% and absence of serum ferritin\> 800) in the same manner as week 1.
Study: NCT02213653
Drug: ARM C : single epoietin zeta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoietin zeta at a dose of 450 IU / kg per week subcutaneously begun in week 1
Study: NCT01611857
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: The FOLFOX treatment regimen is started on Day 1 of each cycle and consists of 5-Fluorouracil (5-FU) 400 mg/m\^2, 5-FU continuous IV 2400 mg/m\^2 over 46 hours, leucovorin 400 mg/m\^2 IV, and oxaliplatin 85 mg/m\^2.
Study: NCT00582010
Drug: inhaled nitric oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled 80ppm for duration of surgery.
Study: NCT03201445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match filgotinib tablet administered orally once daily
Study: NCT03201445
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locally approved treatment, accepted by medical experts as a proper treatment for IBD conditions, prescribed according to best clinical practice, with no known testicular toxicity.
Study: NCT02934191
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosing will be 6mg/kg twice a day with a maximum dose of 300mg twice a day. All ages will be given the suspension (concentration 100mg/5mL) orally
Study: NCT02934191
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen syrup at a dose of 15mg/kg/dose will be given every 4 hours for the first 5 days after surgery. After that point, is given as needed.
Study: NCT04166565
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 300 mg/m2 will be administered as a p.o. or i.v. weekly dose (Days 1, 8, 15, and 22) in every 28-day cycle (maximum weekly dose 500 mg).~Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o.
Study: NCT02806115
Drug: Acetic Acid
Normalized name: Acetic acid
DrugBank: Acetic acid (DB03166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The concentration of acetic acid used in this study is 1.5%.
Study: NCT01931878
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject may be randomly assigned to receive Placebo which is an inactive test substance which has no active ingredient. In this protocol we use sterile salt water as placebo.This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is placebo, the second injections after a three month interval will be active study drug. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
Study: NCT00237393
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
Study: NCT00841828
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00789035
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01425658
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The Fentanyl group (group F) received bupivacaine 10mg combined with 25 microgram fentanyl intrathecally .
Study: NCT01932918
Drug: Patient controlled analgesia
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. PCA with morphine in liver transplant:~   Intravenous patient controlled analgesia with morphine was used for postoperative pain control in liver transplant recipients.~2. PCA with morphine and ketorolac:~   Patient controlled analgesia with morphine and ketorolac was used for postoperative pain control in liver transplant and thoracic surgery patients.~3. Intravenous PCA in thoracic surgery Intravenous patient controlled analgesia was used for postoperative pain control in thoracic surgery patients.~4. PCEA in thoracic surgery Patient controlled epidural analgesia was used for postoperative pain control in thoracic surgery patients.
Study: NCT02128321
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT04648800
Drug: BCG-10 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The BCG-10 anti-tuberculosis vaccine~* powder and solvent for preparing a suspension for intradermal injections of Vaccinum tuberculosis (BCG) cryodesiccatum;~* lyophilised BCG vaccine~* one dose (0.1 ml) contains 50 micrograms of half-dried mass of BCG mycobacteria, which corresponds to 150,000 - 600,000 of live BCG bacilli- the Brazilian Moreau sub-strain.
Study: NCT04648800
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline